YükselKarkınKüçük Attorney Partnership (YKK) is a leading full service law firm, with a team of over 100 lawyers including 12 partners, offering tailored legal assistance to domestic and multinational corporations and financial institutions. Our main objective is to provide value-added service with a result-oriented approach.
Our nine departments (Corporate, Dispute Resolution, Intellectual Property and Technology, Finance and Projects, Competition, Employment, Real Estate, Tax and White Collar Crime) works closely with each other so that our clients’ needs are met by provision of specialised legal work arising both during the course of their daily businesses and in connection with potential investment decisions. With our specialised expertise and increased number of attorneys, we strive to give the best quality service to our clients in large scaled and complex transactions as well as extraordinary situations encountered by our clients that may challenge their daily businesses and investments. This is important for our clients because our firm stands as the single solution address for legal assistance regarding different kinds of legal questions and challenges faced by our clients, both in Turkey and worldwide.
With deep industry-specific knowledge and a understanding of trade dynamics, we aim to provide the best possible solution for our clients to reach their goals and business objectives. Working in today’s global environment requires us to understand our clients thoroughly. Our practice combines worldwide reach with comprehensive local knowledge which enables us to deliver successful outcomes. We prioritise our clients’ business needs and are we easily accessible at all times.
Chambers Europe, one of the world’s leading and most reputable legal directories, has awarded our firm with the Chambers Europe award for Excellence “Turkey- Law Firm of the Year 2012”, making YKK the “first winner” of this outstanding award in Turkey. YKK has also been awarded “Turkey- Law Firm of the Year 2013” at the Chambers Europe Award for Excellence.
Furthermore, we were ranked number one in deal volume according to MergerMarket data in 2012 and 2013 with 13 and 16 deals (in terms of number of deals that were credited according to MergerMarket criteria) respectively. In 2014, we ranked number one on both in the Deal Count and Deal Value tables of Mergermarket’s 2014 Turkey M&A Trend Report and Legal Adviser League Tables. According to the report YükselKarkınKüçük Attorney Partnership achieved ranked first by accomplishing 26 deals with total value over USD 5 billion in 2014.
The STAR (Socar Turcas Aegean Refinery) Project, advised by our Finance and Projects Department, has been awarded in 3 categories; Project Finance Deal of the Year, Weber Shandwick Trade and Export Deal of the Year, and one of the most prestigious awards in the sector, Syndicated Loan Deal of the Year by Bonds & Loans Awards.
Additionally we garnered the “Turkey Legal Adviser Award” in the Mergermarket 2014 European M&A Award Ceremony held at the Savoy Hotel, in London on 11 December 2014.
For more information about our partnership, you can visit www.yukselkarkinkucuk.av.tr
Contact Details
Büyükdere Cad. No: 127 Astoria Tower
A Floors: 6-7-24-25-26-27, Tower B Floor 24
34394 ESENTEPE
İstanbul / TÜRKİYE
Tel: +90 212 318 0505
Fax: +90 212 318 0506
Email: info@yukselkarkinkucuk.av.tr
A founding partner of YükselKarkınKüçük, Gökhan Gökçe discusses the firm’s involvement with several high profile cases concerning the healthcare and life science sector’s reference pricing system, and also elaborates on…
A roundup of the biggest pharma and healthcare stories from Turkey including the investigation of 19 pharma companies by the country’s competition watchdog; Gen Pharma Caucasus Manufacturing’s new plant in…
A roundup of the latest pharma and healthcare news from Turkey including Omya’s new Turkish manufacturing site, Santa Farma’s fourth EU-GMP certification and the collaboration agreement between BioNTech and Turkey’s…
A roundup of the latest pharma and healthcare news from Turkey including Roche Turkey’s digital platform for HCPs and patients, big pharma’s aid to earthquake victims, the Scientific and Technological…
The Middle East and Africa (MEA), the fifth-largest regional pharma market in the world, is rapidly becoming a pharmaceutical powerhouse with both global and local firms taking advantage of the…
After its best financial year to date – posting revenues of USD 27.3 billion in 2021 – Gilead has said yes to localization in Turkey. The California-based company, known for…
Turkey’s pharma market, the 18th largest in the world and valued at USD 7 Billion in 2020, has seen steady growth over the past few years due to favorable healthcare…
With an already well-established manufacturing industry for pharmaceuticals, Turkey has been aiming to move with global trends and invest in biologics production, specifically in biosimilars. The share of biotechnological…
Becoming the clinical trials country leader in the region has been set as a primary goal for Turkey’s pharma industry to achieve global competitiveness. The government’s strategy is to increase…
Few Turkish companies are experiencing such a transformational moment as GEN. In 2021 alone, the Ankara-based organization made its public debut on the Istanbul Stock Exchange and signed an exclusive…
When the Turkish Ministry of Health implemented its strategy to transition from import pharmaceuticals to manufacturing them at home in 2016, the local industry leveraged the situation to invest in…
As an upper-middle-income country with an emerging economy, Turkey could not invest billions in COVID-19 vaccine R&D, but a strong research ecosystem and willing industry allowed it to kickstart multiple…
Overseeing healthcare for a population of over 80 million, Turkey’s Ministry of Health was put under the spotlight during the COVID-19 pandemic. Here, we highlight four of the hot-button items…
See our Cookie Privacy Policy Here
